SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Raises Price Target to $125

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $104 to $125.

Benzinga · -

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $104 to $125.